Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials
2016
The oral tyrosine kinase inhibitors (TKI) dasatinib, imatinib, ponatinib, nilotinib and bosutinib each target BCR-ABL, yet are structurally distinct from one another.1, 2, 3, 4, 5, 6 The selection of BCR-ABL TKI treatment for an individual patient is influenced by factors including any previous treatment, likelihood of benefit, risk of toxicities and the potential for end-organ damage resulting from use, particularly as a long-term therapy is expected in chronic myeloid leukemia in chronic phase (CML-CP). Despite considerable overlap of safety profiles, there are distinct drug-specific adverse events associated with each TKI.2
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
7
References
11
Citations
NaN
KQI